Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 1.58B P/E - EPS this Y 66.70% Ern Qtrly Grth -
Income 95.69M Forward P/E -211.00 EPS next Y 400.00% 50D Avg Chg -56.00%
Sales 346.72M PEG - EPS past 5Y - 200D Avg Chg -38.00%
Dividend N/A Price/Book 53.28 EPS next 5Y - 52W High Chg -70.00%
Recommedations 2.10 Quick Ratio 2.77 Shares Outstanding 154.82M 52W Low Chg 117.00%
Insider Own 9.59% ROA 20.47% Shares Float 133.47M Beta 2.21
Inst Own 61.05% ROE 87.78% Shares Shorted/Prior 29.84M/32.72M Price 10.55
Gross Margin 92.76% Profit Margin 27.60% Avg. Volume 4,329,672 Target Price 34.29
Oper. Margin 12.00% Earnings Date Oct 30 Volume 12,845,372 Change 0.57%
About TG Therapeutics, Inc.

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.

TG Therapeutics, Inc. News
12/17/24 High Growth Tech Stocks To Watch In The United States
11/29/24 TG Therapeutics to Participate in the Evercore HealthCONx Conference
11/26/24 TG Therapeutics price target raised to $43 from $30 at JPMorgan
11/21/24 TG Therapeutics Ranked Number One Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500™
11/12/24 Exploring 3 High Growth Tech Stocks in the United States
11/07/24 TG Therapeutics, Inc. Just Missed Earnings - But Analysts Have Updated Their Models
11/05/24 TG Therapeutics Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
11/05/24 TG Therapeutics Inc (TGTX) Q3 2024 Earnings Call Highlights: Record Revenue Growth and ...
11/05/24 Q3 2024 TG Therapeutics Inc Earnings Call
11/04/24 AI Stocks Meta, Oracle Lead Five Names Near Buy Points
11/04/24 TG Therapeutics Crashes — Reversing A Breakout — After Missing 'Whisper' Expectations
11/04/24 TG Therapeutics (TGTX) Lags Q3 Earnings Estimates
11/04/24 TG Therapeutics: Q3 Earnings Snapshot
11/04/24 TG Therapeutics Reports Third Quarter 2024 Financial Results and Raises BRIUMVI® (ublituximab-xiiy) Full Year Revenue Guidance
11/01/24 TG Therapeutics to Host Conference Call on Third Quarter 2024 Financial Results and Business Update
10/31/24 Is TG Therapeutics, Inc. (TGTX) Set to Explode in 2025?
10/14/24 High Growth Tech Stocks to Watch in October 2024
09/20/24 TG Therapeutics Inc (TGTX): Short Seller Sentiment is Bearish
09/19/24 Are Robust Financials Driving The Recent Rally In TG Therapeutics, Inc.'s (NASDAQ:TGTX) Stock?
09/18/24 IBD 50's TG Therapeutics Rises On Five-Year Data For Multiple Sclerosis Drug
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Charney Laurence N Director Director Jan 05 Sell 19.03 17,500 333,025 237,229 01/08/24
Power Sean A CFO CFO Jan 03 Sell 16.91 47,867 809,431 606,969 01/05/24
WEISS MICHAEL S CEO and President CEO and President Aug 11 Buy 10.13 100,000 1,013,000 12,073,021 08/14/23
Lonial Sagar Director Director Jun 23 Sell 23.370 34,854 814,538 93,878 06/26/23
Power Sean A Chief Financial Offi.. Chief Financial Officer Jun 02 Sell 26.70 73,647 1,966,375 654,836 06/05/23
Echelard Yann Director Director Jan 06 Buy 10.64 9,000 95,760 201,848 01/06/23
Charney Laurence N Director Director Jan 04 Sell 11.10 30,000 333,000 234,729 01/06/23
Power Sean A CFO, Secretary and T.. CFO, Secretary and Treasurer Jan 04 Sell 18.76 84,965 1,593,943 568,483 01/07/22
WEISS MICHAEL S CEO and President CEO and President Dec 29 Sell 18.76 68,220 1,279,807 10,988,021 01/07/22